Home » Stocks » Parnell Pharmaceuticals Holdings

Parnell Pharmaceuticals Holdings Ltd. (PARNF)

Stock Price: $0.140 USD -0.010 (-6.67%)
Updated Aug 5, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 2.54M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 18.15M
EPS (ttm) -1.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 5, 2020
Last Price $0.140
Previous Close $0.150
Change ($) -0.010
Change (%) -6.67%
Day's Open 0.140
Day's Range 0.140 - 0.140
Day's Volume 1,000
52-Week Range 0.040 - 0.360

More Stats

Market Cap 2.54M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 18.15M
Float n/a
EPS (basic) n/a
EPS (diluted) -1.05
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 27,414
Short Ratio 0.29
Short % of Float 0.42%
Beta 2.61
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA 4.11%
ROE n/a
ROIC n/a
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$11.24*
Low
11.2
Current: $0.140
High
11.2
Target: 11.24
*Average 12-month USD price target from 1 stock analysts.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name Parnell Pharmaceuticals Holdings Ltd.
CEO Brad R. McCarthy

Stock Information

Ticker Symbol PARNF
Stock Exchange US OTC
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier OTCMKTS: PARNF
IPO Date June 18, 2014

Description

Parnell Pharmaceuticals Holdings Ltd, a veterinary pharmaceutical company, focuses on developing, manufacturing, and commercializing various animal health solutions. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for improving cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product aids in the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also operates mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.